# A Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 and Rilpivirine and Dolutegravir and Rilpivirine in Healthy Adult Subjects

> **NCT01467531** · PHASE1 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 28 (actual)

## Conditions studied

- Infections, Human Immunodeficiency Virus and Hepatitis

## Interventions

- **DRUG:** Dolutegravir
- **DRUG:** Rlipivirine
- **DRUG:** GSK1265744

## Key facts

- **NCT ID:** NCT01467531
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2012-10-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01467531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01467531, "A Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 and Rilpivirine and Dolutegravir and Rilpivirine in Healthy Adult Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01467531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*